175 related articles for article (PubMed ID: 32870996)
1. A "Split" Hemoglobin S Peak.
Colby JM; Shajani-Yi Z
Clin Chem; 2020 Sep; 66(9):1250-1251. PubMed ID: 32870996
[No Abstract] [Full Text] [Related]
2. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
[No Abstract] [Full Text] [Related]
3. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
5. The effect of Voxelotor on quantitation of HbS levels by high-performance liquid chromatography in a patient with sickle cell disease.
Giacomini L; Puricelli C; Sacchetti S; Zanotti V; Rolla R
Int J Lab Hematol; 2023 Dec; 45(6):831-832. PubMed ID: 37604778
[No Abstract] [Full Text] [Related]
6. How do we monitor hemoglobin S in patients who undergo red blood cell exchange and take voxelotor?
Godbey EA; Anderson MR; M Bachmann L; Sanford KW; Wieditz K; Roseff SD
Transfusion; 2021 Jun; 61(6):1680-1683. PubMed ID: 33880770
[No Abstract] [Full Text] [Related]
7. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
[TBL] [Abstract][Full Text] [Related]
8. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J
Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314
[TBL] [Abstract][Full Text] [Related]
10. Hb S (
Tsitsikas DA; Kamal M; Braimoh A; Benson S; Abukar J
Hemoglobin; 2021 Nov; 45(6):355-357. PubMed ID: 33622152
[TBL] [Abstract][Full Text] [Related]
11. Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Ballas SK; Kuypers FA; Gordeuk VR; Hankins JS; Thompson AA; Vichinsky E
Br J Haematol; 2021 Nov; 195(4):518-522. PubMed ID: 34131897
[TBL] [Abstract][Full Text] [Related]
12. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.
Estepp JH
Am J Hematol; 2018 Mar; 93(3):326-329. PubMed ID: 29352729
[No Abstract] [Full Text] [Related]
13. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
[TBL] [Abstract][Full Text] [Related]
15. Arriving at a Number: What Hemoglobin S Level to Select During an Emergent RBC Exchange for Patients on Voxelotor.
Booth GS
Am J Clin Pathol; 2021 May; 155(6):912. PubMed ID: 33928342
[No Abstract] [Full Text] [Related]
16. Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
Çanak B; Eşkazan AE
Br J Clin Pharmacol; 2022 Jun; 88(6):2564-2565. PubMed ID: 35158414
[No Abstract] [Full Text] [Related]
17. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
18. Blocking HbS Polymerization in SCD.
Lettre G
Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
[TBL] [Abstract][Full Text] [Related]
19. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action.
Suhail M
Sci Rep; 2024 Jan; 14(1):1861. PubMed ID: 38253605
[TBL] [Abstract][Full Text] [Related]
20. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.
Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS
Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]